The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | KEYNOTE-189 update: 4-year follow-up of FL pembro +chemo metastatic NSCLC
Nir Peled, MD, PhD, Sackler Faculty of Medicine, Tel Aviv University, Israel, discusses the updated efficacy and safety results of the Phase III KEYNOTE-189 trial (NCT02578680) of pemetrexed-platinum chemotherapy with or without pembrolizumab in patients with non-small cell lung cancer (NSCLC) after 4 years of follow-up. Over 600 patients with untreated metastatic nonsquamous NSCLC were randomized 2:1 to receive intravenous pembrolizumab or placebo. The long-term follow-up data showed that the addition of pembrolizumab provided a significant benefit to progression-free survival and overall survival, compared with chemotherapy alone. The substantial prolongation was seen irrespective of PD-L1 expression. The findings continue to support those reported at earlier time points. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
